Press Releases
The seasoned life sciences executive will play a key role as the company completes the regulatory process and prepares for commercialization of its Neuspera SNM System SAN JOSE, Calif., Sept. 12, 2024 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Sacral Neuromodulation (SNM) System, announced today that Bunty Banerjee has joined the company as its first Chief Operating […]
Clinical study data to evaluate the safety and efficacy of the Neuspera System for the treatment of urinary urge incontinence (UUI) will support the FDA submission for regulatory approval SAN JOSE, Calif., July 23, 2024 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, announced it has reached a significant milestone: All […]
Capital from Olympus Innovation Ventures, another strategic investor and several institutional investors will fund through expected PMA approval SAN JOSE, Calif., July 15, 2024 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, announced the closing of its Series D funding round raising $23 million and led by Vertex Ventures HC and Treo […]
The international study is evaluating the safety and efficacy of the Neuspera System for the treatment of urinary urge incontinence (UUI), a symptom of overactive bladder (OAB) SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, today announced it has completed patient enrollment and implant procedures […]
The nationwide study is evaluating the safety and efficacy of the Neuspera System for the treatment of urinary urge incontinence (UUI), a symptom of overactive bladder (OAB) SAN JOSE, Calif. , Nov. 14, 2023 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, today announced the completion of the 100th implant of its Neuspera […]
First-of-its-kind, leadless micro-implant for chronic peripheral nerve pain management SAN JOSE, Calif., April 18, 2023 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it received U.S. Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturized system. The system is comprised of a micro-implant that delivers neurostimulation […]
SAN JOSE, CA – February 1, 2023 — Neuspera® Medical, a medical device company developing miniaturized neuromodulation technology for patients with chronic illnesses, announces the hiring of Courtney Lane as Vice President, Clinical and Regulatory Affairs. The fast-growing early-stage company is progressing through enrollment of the second stage of its pivotal study (SANS-UUI) to evaluate […]
Study to support U.S. FDA approval of sacral neuromodulation device in patients with urinary urgency incontinence symptoms SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced the first patient successfully implanted with the Nuvella™ system in its pivotal clinical trial (SANS-UUI). The […]
Hovard brings a wealth of medical device senior leadership experience to the company as it works to advance sacral neuromodulation therapies SAN JOSE, Calif., Sept. 6, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable medical device technology for patients with chronic illness, today announced the hiring of seasoned medtech executive, Steffen Hovard as Chief Executive Officer. […]
San Jose, CA – August 4, 2022– Neuspera® Medical, a medical device company developing implantable medical device technology for patients battling chronic illness, today announced the hiring of Steven Siegel, MD, as Chief Medical Officer. Dr. Siegel joined Neuspera as the company recently began enrollment of the second phase of their pivotal clinical trial (SANS-UUI). […]